Compare Amphastar Pharmaceuticals Inc (AMPH) vs 8x8 Inc (EGHT) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

EGHT trades at $2.05, down 0.49% today, with a bullish technical signal from moving averages. The company shows strong revenue growth with Q4 2026 earnings beating estimates at $0.11 per share versus $0.07 expected. Recent positive news includes AI product launches and industry recognition, though profitability remains weak with a net margin of just 0.22% and negative retained earnings of -$887.72 million.

Outlook is mixed with analyst consensus leaning neutral (39% buy, 43% hold). Key opportunities include AI-driven product expansion and consistent earnings beats, while risks involve high debt levels, thin margins, and competitive pressures in the CPaaS space. The stock's high P/E ratio of 205 suggests growth expectations are priced in.